晚期非小细胞肺癌患者循环肿瘤细胞与白细胞PD-L1检测
该研究纳入106例晚期NSCLC患者,采用ISET平台富集外周血循环肿瘤细胞(CTC)和白细胞,以自动免疫组化(SP142抗体)评估PD-L1表达,并与配对肿瘤组织比较。结果显示CTC与组织PD-L1状态一致率93%,循环白细胞与组织免疫浸润PD-L1一致率80%,提示CTC检测可作为无创实时活检评估PD-L1状态的潜在方法。
要点
- CTC与肿瘤组织PD-L1状态一致率达93%,特异性100%。
- 循环白细胞与组织免疫浸润PD-L1一致率80%,灵敏度82%。
- CTC或免疫细胞PD-L1阳性者一线顺铂化疗生存有更差趋势。
核心结论
- CTC和循环白细胞的PD-L1状态与肿瘤组织PD-L1状态相关,CTC评估有潜力作为无创实时活检用于晚期NSCLC患者PD-L1表达评价。
研究设计与样本
- 从106例晚期NSCLC患者外周血样本中用ISET平台富集CTC和循环白细胞。
- 用自动免疫组化(SP142抗体;Ventana)评估ISET滤膜与配对肿瘤组织的PD-L1表达,并在肿瘤细胞和白细胞中定量。
主要发现
- 80例(75%)患者检出CTC,水平范围2至256个CTC/4 ml,中位60个CTC/4 ml。
- 71例有配对组织和CTC的可评估样本中,6例(8%)有≥1个PD-L1阳性CTC,11例(15%)肿瘤组织有≥1% PD-L1阳性肿瘤细胞,组织与CTC一致率93%(灵敏度55%;特异性100%)。
- 74例有配对组织和循环白细胞样本中,40例(54%)肿瘤组织免疫浸润≥1% PD-L1阳性,39例(53%)循环白细胞≥1% PD-L1阳性,血液与组织一致率80%(灵敏度82%;特异性79%)。
- 接受一线顺铂为基础化疗且CTC或免疫细胞PD-L1阳性的患者,无进展生存和总生存有更差趋势,与配对肿瘤PD-L1表达效应相似。
临床怎么用
- CTC和循环白细胞PD-L1检测与组织PD-L1状态一致,可考虑作为无创方法辅助评估晚期NSCLC患者PD-L1状态。
局限性
- CTC与组织PD-L1一致率虽高但灵敏度仅55%,可能漏检部分PD-L1阳性患者。
- 循环白细胞与组织PD-L1一致率80%,灵敏度和特异性分别为82%和79%,存在一定误判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Expression of PD-L1 in tumor cells and tumor-infiltrating immune cells has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors in patients with advanced-stage non-small-cell lung cancer (NSCLC) and emerged as a potential biomarker for the selection of patients to cancer immunotherapies. We investigated the utility of circulating tumor cells (CTCs) and circulating white blood cells (WBCs) as a noninvasive method to evaluate PD-L1 status in advanced NSCLC patients. PATIENTS AND METHODS: CTCs and circulating WBCs were enriched from peripheral blood samples (ISET® platform; Rarecells) from 106 NSCLC patients. PD-L1 expression on ISET filters and matched-tumor tissue was evaluated by automated immunostaining (SP142 antibody; Ventana), and quantified in tumor cells and WBCs. RESULTS: CTCs were detected in 80 (75%) patients, with levels ranging from 2 to 256 CTCs/4 ml, and median of 60 CTCs/4 ml. Among 71 evaluable samples with matched-tissue and CTCs, 6 patients (8%) showed ≥1 PD-L1-positive CTCs and 11 patients (15%) showed ≥1% PD-L1-positive tumor cells in tumor tissue with 93% concordance between tissue and CTCs (sensitivity = 55%; specificity = 100%). From 74 samples with matched-tissue and circulating WBCs, 40 patients (54%) showed ≥1% PD-L1-positive immune infiltrates in tumor tissue and 39 patients (53%) showed ≥1% PD-L1 positive in circulating WBCs, with 80% concordance between blood and tissue (sensitivity = 82%; specificity = 79%). We found a trend for worse survival in patients receiving first-line cisplatin-based chemotherapy treatments, whose tumors express PD-L1 in CTCs or immune cells (progression-free and overall survival), similar to the effects of PD-L1 expression in matched-patient tumors. CONCLUSIONS: These results demonstrated that PD-L1 status in CTCs and circulating WBCs correlate with PD-L1 status in tumor tissue, revealing the potential of CTCs assessment as a noninvasive real-time biopsy to evaluate PD-L1 expression in patients with advanced-stage NSCLC.
引用
- Ilié M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol. 2018. PMID: 29361135. doi:10.1093/annonc/mdx636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。